What is Redcliffe Genetics?
Redcliffe Genetics, established in 2004 and headquartered in Noida, India, operates within the critical field of genetic sequencing and diagnostics. The company leverages advanced technologies to provide insights into genetic information, aiming to improve healthcare outcomes through precise diagnostic solutions. Its focus on genetic analysis positions it at the forefront of personalized medicine and disease prevention.
How much funding has Redcliffe Genetics raised?
Redcliffe Genetics has raised a total of $61M across 1 funding round:
Series B
$61M
Series B (2022): $61M with participation from LeapFrog Investments
Key Investors in Redcliffe Genetics
LeapFrog Investments
LeapFrog Investments is a prominent investment firm focused on backing exceptional businesses in Africa and emerging Asia, with a strategic emphasis on achieving significant growth, profitability, and positive impact. Based in London, England, they partner with leaders to drive transformative development.
What's next for Redcliffe Genetics?
With a recent major strategic investment, Redcliffe Genetics is poised for accelerated expansion. The capital infusion is expected to fuel advancements in its diagnostic platforms, enhance research and development initiatives, and broaden its service offerings. This strategic backing will likely enable Redcliffe Genetics to solidify its market position, explore new therapeutic areas, and potentially expand its geographical footprint, further contributing to the evolution of genetic diagnostics.
See full Redcliffe Genetics company page
